Lung imaging in asthmatic patients: The picture is clearer - 28/08/11
, Sean B. Fain, PhD b, Eric A. Hoffman, PhD c, David S. Gierada, MD a, Serpil C. Erzurum, MD d, Sally Wenzel, MD eNational Heart, Lung, and Blood Institute’s Severe Asthma Research Program
Reprint requests: Mario Castro, MD, MPH, Washington University School of Medicine, Campus Box 8052, 660 S Euclid, St Louis, MO 63110-1093.Abstract |
Imaging of the lungs in patients with asthma has evolved dramatically over the last decade with sophisticated techniques, such as computed tomography, magnetic resonance imaging, positron emission tomography, and single photon emission computed tomography. New insights into current and future modalities for imaging in asthmatic patients and their application are discussed to potentially shed a clearer picture of the underlying pathophysiology of asthma, especially severe asthma, and the proposed clinical utility of imaging in patients with this common disease.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, imaging, chest computed tomography, magnetic resonance imaging
Abbreviations used : ADC, CT, EBUS, FDG, FRC, HP He, HU, MDCT, MRI, OCT, PET, RV, SARP, SPECT, 99mTc-HMPAO, TLC, WA, WT
Plan
| Supported by National Institutes of Health/National Heart, Lung, and Blood Institute grants HL69149, HL64368, HL69349, HL69170, HL-69155, HL69130, HL69167, HL69116, and HL69174 and the Hartwell Foundation (S.B.F.). |
|
| Disclosure of potential conflict of interest: M. Castro is a consultant for Electrocore, NKIT, Schering-Plough, Asthmatx, and Cephalon; is on the advisory board and is a speaker for Genentech; is a speaker for AstraZeneca, Boehringer Ingelheim, Pfizer, Merck, and GlaxoSmithKline; has received royalties from Elsevier; and has received grants from Asthmatx, Amgen, Ception, Genentech, MedImmune, Merck, Novartis, the National Institutes of Health, and GlaxoSmithKline. S. B. Fain is a consultant for and has received research support from GE Healthcare. E. A. Hoffman is a consultant for Roche, Sanofi-Aventis, and Spiration and is a founder and shareholder of VIDA Diagnostics. S. C. Erzurum is owner of Asthmatx. The rest of the authors have declared that they have no conflict of interest. |
Vol 128 - N° 3
P. 467-478 - septembre 2011 Retour au numéro
Article précédent
- Maintenance of certification and maintenance of professionalism
- Stephen I. Wasserman
- Evidence of a genetic contribution to lung function decline in asthma
- Gerard H. Koppelman, Ian Sayers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?